NASDAQ$COGT

Cogent Biosciences Inc · Q3 2019 earnings

Q3 2019 earnings · · Investor relations

Headline financials

Total Revenue

$1.02M

Previous: $2.04M-50.1%
EPS (adj)

-$0.39

Previous: -$0.34-14.7%
R&D expenses

$10.3M

No prior period
G&A expenses

$2.72M

No prior period
Capital Expenditures

-$20K

Previous: -$549K+96.4%
Free Cash Flow

-$11.9M

Previous: -$10.7M-11.4%
Net Income

-$11.9M

Previous: -$10.2M-17.3%
Operating Income

-$12M

Previous: -$10.6M-13.8%
Gross Profit

-$9.32M

Previous: $2.04M-555.9%
Cash & Equivalents

$45.9M

Previous: $49.3M-6.9%
Total Assets

$57.9M

Previous: $94.8M-38.9%
Stock-Based Comp

$788K

Previous: $860K-8.4%

Revenue & EPS history

Cogent Biosciences · Revenue · Quarterly

$1.02M

Q3 2019-50.1%vs Q3 2018
Beat estimate in 4 of 8 quarters(50%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2019

Historical avgQ3 2019

+0.9%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+4.5%

Avg return

30 days after

65%

20 / 31 earnings

Positive

+17.8%

Q3 2018

Best reaction

-24.0%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%-5.3%-10.6%
Q3 2025-4.4%-9.1%+140.2%
Q2 2025-5.8%-9.0%+7.4%
Q1 2025+2.7%+4.4%+48.4%
Q4 2024-6.3%+0.9%-11.4%
Q3 2024+0.0%-14.4%-19.8%
Q1 2024+0.4%-0.1%+11.1%
Q4 2023+0.7%-2.8%-12.4%
Q3 2023+3.9%+3.8%-2.7%
Q2 2023+7.3%+8.8%+9.4%
Q1 2023-1.5%-2.6%-2.9%
Q4 2022+0.7%-5.1%-13.7%
Q3 2022-5.7%-8.5%-2.6%
Q2 2022+9.6%+12.1%+32.7%
Q1 2022-24.0%-26.8%-10.6%
Q4 2021+4.5%+28.4%+64.6%
Q3 2021+13.7%+12.1%-9.9%
Q2 2021+5.4%+13.4%+3.3%
Q1 2021+1.7%+4.9%+4.0%
Q4 2020+5.9%+5.5%+9.0%
Q3 2020+13.2%+9.8%+14.9%
Q2 2020-11.4%-11.0%-8.3%
Q1 2020+0.5%+17.9%+37.1%
Q4 2019-3.1%-15.5%-18.6%
Q3 2019-10.2%-32.6%-52.1%
Q2 2019+4.4%+9.3%+9.0%
Q1 2019+0.2%-1.1%-26.2%
Q4 2018+8.1%+5.4%-12.3%
Q3 2018+17.8%+18.5%-25.0%
Q2 2018-5.9%-12.8%-27.3%
Q1 2018+4.0%+12.4%+13.6%
Q4 2017
Q3 2017
Q2 2017
Q1 2017
Q3 2016
Q3 2015

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro